Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity : clinical outcomes in advanced melanoma

Y J L Jansen; E A Rozeman; R Mason; S M Goldinger; Foppen M H Geukes; L Hoejbergs; H Schmidt; JV van Thienen; J B A G Haanen; L Tiainen; I M Svane; S Mäkelä; T Seremet; A Arance; R Dummer; L Bastholt; M Nyakas; O Straume; A M Menzies; G V Long; V Atkinson; C U Blank

doi:10.1093/annonc/mdz110

Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity : clinical outcomes in advanced melanoma

Y J L Jansen
, E A Rozeman
, R Mason
, S M Goldinger
, Foppen M H Geukes
, L Hoejbergs
, H Schmidt
, JV van Thienen
, J B A G Haanen
, L Tiainen
, I M Svane
, S Mäkelä
, T Seremet
, A Arance
, R Dummer
, L Bastholt
, M Nyakas
, O Straume
, A M Menzies
, G V Long

V Atkinson, C U Blank

Research output: Contribution to journal › Article › Scientific › peer-review

207 Citations (Scopus)

Original language	English
Pages (from-to)	1154-1161
Journal	Annals of Oncology
Volume	30
Issue number	7
DOIs	https://doi.org/10.1093/annonc/mdz110
Publication status	Published - 2019
Publication type	A1 Journal article-refereed

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

anti-PD-1 therapy
duration of treatment
immunotherapy
melanoma

Publication forum classification

Publication forum level 2

Access to Document

10.1093/annonc/mdz110

Cite this

Jansen, Y. J. L., Rozeman, E. A., Mason, R., Goldinger, S. M., Geukes, F. M. H., Hoejbergs, L., Schmidt, H., van Thienen, JV., Haanen, J. B. A. G., Tiainen, L., Svane, I. M., Mäkelä, S., Seremet, T., Arance, A., Dummer, R., Bastholt, L., Nyakas, M., Straume, O., Menzies, A. M., ... Blank, C. U. (2019). Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity : clinical outcomes in advanced melanoma. Annals of Oncology, 30(7), 1154-1161. https://doi.org/10.1093/annonc/mdz110

@article{035951915ff84484b5ad98ebe5f07460,

title = "Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity : clinical outcomes in advanced melanoma",

keywords = "anti-PD-1 therapy, duration of treatment, immunotherapy, melanoma, anti-PD-1 therapy, duration of treatment, immunotherapy, melanoma",

author = "Jansen, \{Y J L\} and Rozeman, \{E A\} and R Mason and Goldinger, \{S M\} and Geukes, \{Foppen M H\} and L Hoejbergs and H Schmidt and \{van Thienen\}, JV and Haanen, \{J B A G\} and L Tiainen and Svane, \{I M\} and S M{\"a}kel{\"a} and T Seremet and A Arance and R Dummer and L Bastholt and M Nyakas and O Straume and Menzies, \{A M\} and Long, \{G V\} and V Atkinson and Blank, \{C U\}",

year = "2019",

doi = "10.1093/annonc/mdz110",

language = "English",

volume = "30",

pages = "1154--1161",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Elsevier",

number = "7",

}

Jansen, YJL, Rozeman, EA, Mason, R, Goldinger, SM, Geukes, FMH, Hoejbergs, L, Schmidt, H, van Thienen, JV, Haanen, JBAG, Tiainen, L, Svane, IM, Mäkelä, S, Seremet, T, Arance, A, Dummer, R, Bastholt, L, Nyakas, M, Straume, O, Menzies, AM, Long, GV, Atkinson, V & Blank, CU 2019, 'Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity : clinical outcomes in advanced melanoma', Annals of Oncology, vol. 30, no. 7, pp. 1154-1161. https://doi.org/10.1093/annonc/mdz110

TY - JOUR

T1 - Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity : clinical outcomes in advanced melanoma

AU - Jansen, Y J L

AU - Rozeman, E A

AU - Mason, R

AU - Goldinger, S M

AU - Geukes, Foppen M H

AU - Hoejbergs, L

AU - Schmidt, H

AU - van Thienen, JV

AU - Haanen, J B A G

AU - Tiainen, L

AU - Svane, I M

AU - Mäkelä, S

AU - Seremet, T

AU - Arance, A

AU - Dummer, R

AU - Bastholt, L

AU - Nyakas, M

AU - Straume, O

AU - Menzies, A M

AU - Long, G V

AU - Atkinson, V

AU - Blank, C U

PY - 2019

Y1 - 2019

KW - anti-PD-1 therapy

KW - duration of treatment

KW - immunotherapy

KW - melanoma

KW - anti-PD-1 therapy

KW - duration of treatment

KW - immunotherapy

KW - melanoma

U2 - 10.1093/annonc/mdz110

DO - 10.1093/annonc/mdz110

M3 - Article

SN - 0923-7534

VL - 30

SP - 1154

EP - 1161

JO - Annals of Oncology

JF - Annals of Oncology

IS - 7

ER -